Washington, Oct. 14 -- Representative Chip Roy issued the following press release:
Washington, D.C. - Today, Congressman Chip Roy (TX-21) sent a letter to Food and Drug Administration (FDA) Acting Commissioner Kyle Diamantas demanding answers after the agency indicated that its safety review of mifepristone would not be completed until March 2027, despite assurances that the Biden Administration's January 2023 modifications to the drug's dispensing requirements would be addressed by fall 2026. Those modifications eliminated the in-person dispensing requirement and expanded distribution through the mail.
Rep. Roy wrote: "House Republicans cannot be expected to continue funding the implementation of the January 2023 REMS modifications indefi...